Sodium Iodide Symporter and Phosphatase and Tensin Homolog Deleted on Chromosome Ten Expression in Cholangiocarcinoma Analysis with Clinicopathological Parameters
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: This study was performed to investigate the correlation of sodium iodide symporter (NIS) expression with the functionality and loss of phosphatase and tensin homolog deleted on chromosome ten (PTEN) expression in human cholangiocarcinoma (CCA). Methods: Immunohistochemistry for the expression of NIS and PTEN was performed in 60 biopsy specimens of CCA. The clinicopathological parameters were retrospectively identified from medical records. The expression pattern of NIS and loss of PTEN expression were analyzed in association with the clinicopathological characteristics, including survival. Results: Normal biliary trees displayed NIS expression, but hepatocytes did not. NIS expression was divided into two patterns: cytoplasmic and membranous. Fifty-nine cases, all except for one case, displayed NIS expression in tumor cells. Twenty-two cases (33.3%) were mixed pattern, and 39 cases (65.05%) were cytoplasmic pattern; the pure membranous pattern was not noted. There was no association between the NIS expression pattern and clinicopathological parameters, including age, sex, differentiation grade, T stage and tumor, node, metastasis stage (p>0.05). The survival rates were similar among various NIS expression patterns. Normal hepatocytes and biliary trees exhibited PTEN expression in the nucleus and cytoplasm. CCA cells displayed nuclear staining. Thirty-six (60.0%) of 60 cases displayed a loss of PTEN expression. The loss of PTEN expression was observed in the advanced T-stage group (p=0.0036), but there was no association between the loss of PTEN expression and other clinicopathological parameters (p>0.05). No association between the loss of PTEN expression and survival was noted. Conclusions: NIS is expressed in most types of human CCA. The expression pattern suggests a role in cancer development. PTEN loss expression is common in the context of human CCA, especially in the advanced T stage.
Abstract
Background/Aims: This study was performed to investigate the correlation of sodium iodide symporter (NIS) expression with the functionality and loss of phosphatase and tensin homolog deleted on chromosome ten (PTEN) expression in human cholangiocarcinoma (CCA). Methods: Immunohistochemistry for the expression of NIS and PTEN was performed in 60 biopsy specimens of CCA. The clinicopathological parameters were retrospectively identified from medical records. The expression pattern of NIS and loss of PTEN expression were analyzed in association with the clinicopathological characteristics, including survival. Results: Normal biliary trees displayed NIS expression, but hepatocytes did not. NIS expression was divided into two patterns: cytoplasmic and membranous. Fifty-nine cases, all except for one case, displayed NIS expression in tumor cells. Twenty-two cases (33.3%) were mixed pattern, and 39 cases (65.05%) were cytoplasmic pattern; the pure membranous pattern was not noted. There was no association between the NIS expression pattern and clinicopathological parameters, including age, sex, differentiation grade, T stage and tumor, node, metastasis stage (p>0.05). The survival rates were similar among various NIS expression patterns. Normal hepatocytes and biliary trees exhibited PTEN expression in the nucleus and cytoplasm. CCA cells displayed nuclear staining. Thirty-six (60.0%) of 60 cases displayed a loss of PTEN expression. The loss of PTEN expression was observed in the advanced T-stage group (p=0.0036), but there was no association between the loss of PTEN expression and other clinicopathological parameters (p>0.05). No association between the loss of PTEN expression and survival was noted. Conclusions: NIS is expressed in most types of human CCA. The expression pattern suggests a role in cancer development. PTEN loss expression is common in the context of human CCA, especially in the advanced T stage.
참고문헌 (16)
- Khan SA, "Cholangiocarcinoma", Lancet, 366, pp.1303~1314 (2005)
- Lazaridis KN, "Cholangiocarcinoma", Gastroenterology, 128, pp.1655~1667 (2005)
- Sirica AE, "Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy", Hepatology, 41, pp.5~15 (2005)
- Dai G, "Cloning and characterization of the thyroid iodide transporter", Nature, 379, pp.458~460 (1996)
- Spitzweg C, "Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa", J Clin Endocrinol Metab, 83, pp.1746~1751 (1998)
- Spitzweg C, "Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands", J Clin Endocrinol Metab, 84, pp.4178~4184 (1999)
- Spitzweg C, "Expression of the sodium iodide symporter in human kidney", Kidney Int, 59, pp.1013~1023 (2001)
- Knostman KA, "Signaling through 3’,5’-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium", iodide symporter expression in breast cancer, 2004, pp.89, 5196~5203
- Wapnir IL, "Immunohistochemical profile of the sodium", iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections, 2003, pp.88, 1880~1888
- Liu B, "Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma", Gastroenterology, 132, pp.1495~1503 (2007)
- Alvaro D, "Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma", Am J Pathol, 169, pp.877~888 (2006)
- Li J, "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer", Science, 275, pp.1943~1947 (1997)
- Steck PA, "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers", Nat Genet, 15, pp.356~362 (1997)
- Detre S, "A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas", J Clin Pathol, 48, pp.876~878 (1995)
- Spitzweg C, "Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter", Cancer Res, 60, pp.6526~6530 (2000)
- 조형준, "The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma", Clin. Cancer Res., 15, pp.660~667